By Rob Curran
Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial.
Shares of Summit rose 11% to $30.41 premarket trading Thursday.
The Miami biotech firm said its ivonescimab drug met the primary goal of progression-free survival when tested in combination with a platinum-based chemotherapy on patients with a certain type of non-small cell lung cancer.
The Phase 3 clinical trial is being conducted in China in partnership with Chinese biotech firm Akeso to evaluate a combination of ivonescimab and platinum-based chemotherapy against tislelizumab combined with platinum-based chemotherapy in patients with locally advanced or metastatic squamous non-small cell lung cancer irrespective of PD-L1 expression.
Patients taking the ivonescimab regimen saw a statistically significant and clinically meaningful improvement in progression-free survival compared to those taking the tislelizumab regimen, Summit said.
"Ivonescimab has the opportunity to make a significant, positive difference, potentially providing patients with the next generation of treatment options against insidious solid tumors beginning with non-small cell lung cancer," said President and Co-Chief Executive Maky Zanganeh, in a statement.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
April 23, 2025 07:17 ET (11:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。